CD274 and lung adenocarcinoma: PRINCe profiling of serial cfDNA samples from several patients highlighted utility in evaluating treatment response, disease monitoring, and identification of candidate biomarkers of treatment response in a patient (PD-L1006_1) with stage IV lung adenocarcinoma who achieved a complete response to PD-L1 checkpoint inhibition immunotherapy (see Supplementary Results).